Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clarithromycin
Drug ID BADD_D00480
Description Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Indications and Usage An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
Marketing Status Prescription; Discontinued
ATC Code J01FA09
DrugBank ID DB01211
KEGG ID D00276
MeSH ID D017291
PubChem ID 84029
TTD Drug ID D0Z1ZM
NDC Product Code 62135-616; 62332-344; 50090-5282; 43063-752; 70934-507; 50090-4059; 62135-615; 62991-2687; 68071-3116; 0527-1931; 63415-0018; 64679-949; 67296-1632; 49452-2112; 27241-065; 63629-8222; 0781-6023; 38779-1937; 71335-1567; 67296-0464; 60592-429; 43063-823; 50268-178; 57237-045; 76420-051; 61919-643; 71335-0795; 68788-7933; 63629-7832; 68071-5045; 0527-1932; 65862-225; 60687-435; 63187-625; 50268-179; 64679-954; 65862-226; 50090-1830; 43063-520; 71335-0017; 50090-0994; 0781-1961; 27241-064; 67296-1360; 64380-905; 50090-5285; 0904-6872; 46708-829; 43063-942; 70934-905; 51552-1566; 0781-1962; 50090-2441; 43063-565; 43781-0403; 59566-0123; 70518-2773; 15894-0026; 63187-376; 64380-906; 71335-1493; 46708-839; 57237-044; 0395-8158; 0781-6022; 67296-1072; 0051-6552; 70934-530; 51862-194; 0591-2805; 50090-2515; 0527-1930; 53002-7561; 62332-345; 63629-6763; 43063-530; 68788-7125; 43666-0001; 72189-299; 65096-0100
Synonyms Clarithromycin | 6-O-Methylerythromycin | TE-031 | TE 031 | TE031 | A-56268 | A 56268 | A56268 | Biaxin
Chemical Information
Molecular Formula C38H69NO13
CAS Registry Number 81103-11-9
SMILES CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N( C)C)O)(C)OC)C)C)O)(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Torsade de pointesPotassium voltage-gated channel subfamily KQT member 1P51787T4952610219239; 10984545; 10868744
Torsade de pointesMisshapen-like kinase 1Q8N4C8Not Available10219239; 10984545; 10868744
Torsade de pointesPotassium voltage-gated channel subfamily H member 2Q12809T2025110219239; 10984545; 10868744
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oral disorder07.05.01.0050.001234%Not Available
Oropharyngeal blistering22.02.05.025; 07.05.05.0060.001645%Not Available
Cholestatic liver injury09.01.07.0160.002056%Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.0080.001645%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.003702%
Kounis syndrome24.04.04.020; 10.01.03.037; 02.02.02.0200.005347%Not Available
Acute kidney injury20.01.03.0160.011927%
Foetal growth restriction18.03.01.0020.000823%
Posterior reversible encephalopathy syndrome17.13.02.0070.000823%
Functional gastrointestinal disorder07.11.01.016--Not Available
Drug-induced liver injury09.01.07.023; 12.03.01.0440.006169%Not Available
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.000823%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 23.03.05.0050.003290%Not Available
Candida infection11.03.03.021--
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.002468%Not Available
Mouth swelling10.01.05.020; 07.05.04.007; 23.04.01.0200.001234%Not Available
Myocardial necrosis marker increased13.04.01.0130.001234%Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Depersonalisation/derealisation disorder19.14.01.0040.004113%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000823%Not Available
Foetal malnutrition18.03.01.0040.001234%Not Available
Gallbladder non-functioning09.03.02.0070.000823%Not Available
Gastroschisis07.16.06.006; 03.04.07.0090.001234%Not Available
Macroglossia07.14.01.011; 03.04.09.0030.000823%Not Available
Pneumonia pseudomonal22.07.06.014; 11.02.12.0040.001234%Not Available
Respiratory rate increased13.15.01.0040.000823%Not Available
Vitritis06.04.06.0130.000823%Not Available
Multiple-drug resistance08.06.01.0320.001645%Not Available
Urticarial vasculitis24.05.02.027; 23.04.02.012; 10.01.06.0120.001234%Not Available
Live birth18.08.02.0070.001234%Not Available
The 21th Page    First    Pre   21 22    Next   Last    Total 22 Pages